Logo for Altimmune Inc

Altimmune Investor Relations Material

Latest events

Logo for Altimmune Inc

Status Update

Altimmune
Logo for Altimmune

Status Update

13 Mar, 2025
Logo for Altimmune

Q4 2024

27 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies

Latest reports from Altimmune Inc

Access all reports
Altimmune, Inc. engages in the development of immunotherapeutics for infectious and chronic diseases. The company focuses on the development of vaccines and therapeutics for influenza, anthrax and COVID-19. It offers HepTcell, a vaccine candidate to treat Chronic Hepatitis B; AdCOVID, which is an intranasal antigen vaccine to fight COVID-19; NasoVAX, a single dose flu vaccine; T-COVID, an intranasal immune modulating therapeutic candidate; and NasoShield, an anthrax vaccine product candidate. The company was founded by Vipin K. Garg on April 15, 2005 and is headquartered in Gaithersburg, MD.